The antineoplastic drug hexamethylmelamine (HMM) requires metabolic activation, and its activity depends on the presence of methyl moieties in the molecule. It is biotransformed in the liver by N-demethylation, following which the single carbon moiety enters the formaldehyde-formate pool and is mainly excreted as CO2. As part of our investigation into the relationship between HMM metabolism and its mode of action we determined 14CO2 exhalation in a continual fashion in CBA/Lac mice (20-30 g) following i.p. administration of 14CH3-labelled HMM (40 mg/kg) and compared it with the 14CO2 appearance in breath after 38 mg/kg 14CH3-labelled aminopyrine (AP), a non-cytotoxic model substrate of N-demethylases. Whereas the 14CO2 formation rate-time plot for AP peaked rapidly and declined in a biphasic fashion, the corresponding plot for HMM showed a peak after 40-70 min and a monophasic decline with a half life (tl) of 89-7 + 6-6 min (n=5). Peak N-demethylating activity produced 82-5 + 8-0 nmol 14CO2/min (n=4) after AP and 354 + 45 nmol 14CO2/min (n=4) after HMM. Pretreatment with an inhibitor of oxidative drug-metabolizing enzymes (SKF525A, 60 mg/kg i.p. 30 min before drug administration) and an enzyme inducer (phenobarbital, 50 mg/kg i.p. for 4 days) dramatically effected the CO2 data. For HMM the t' of the 14CO2 in the breath after SKF was increased to 264-5 + 21-7 min (n=3); in phenobarbital-pretreated mice the t-was decreased to 69-3 + 107 min (n=4). These results show that pharmacogenic interference with oxidative drug metabolism leads to changed HMM demethylation rates in vivo which may influence its antineoplastic efficacy. PMM is a water-soluble melamine derivative which, unlike hexamethylmelamine (HMM), can be administered clinically in parenteral form. In the present Phase I clinical study PMM was given as an i.v. infusion (100 mg/ m2_1300 mg/M2). Gastrointestinal toxicity (nausea and vomiting) was the major sideeffect observed, as with HMM given orally, which became severe and prolonged (24 h) at doses > 300 mg/M2. Pharmacokinetics and metabolism were monitored in patients by gas chromatography using a nitrogen-specific detector. PMM is eliminated from the plasma with a half-life of 108 min. Two major PMM metabolites were detected in plasma: N2N2N4N6-tetramethylmelamine and N2N4-N6-trimethylmelamine. Pharmacokinetic analyses indicate that i.v. PMM produces higher levels of less extensively demethylated melamines than HM:M administered orally. Hence it may be possible, using PMM, to achieve therapeutic levels of active metabolites at doses xvhich are non-toxic to normal host tissues. Thus PMM may offer a significant therapeutic advantage over HMM. In addition, preliminary evidence from high-performance liquid chromatography analyses suggests the presence of N-methylolmelamines in human plasma. Such compounds are chemically unstable in aqueous solution, releasing formaldehyde at a rate which is highly dependent upon the ionic environment. N-methylolmelamines are more toxic to a number of tumour cell lines in vitro than are the corresponding methylmelamines, and thus may represent the species responsible for the in vivo antitumour activity. Nmethylolmelamines markedly inhibit both DNA and RNA synthesis in vitro, as does formaldehyde. However, these inhibitory effects do not appear to be responsible for the selective cytotoxic action in vivo, where inhibition of nucleic acid synthesis in sensitive tumour cells cannot be shown. Biochem. Pharmacol., Inst. Cancer Res., Sutton, Surrey Cis-dichlorodiammine platinumn (II) (cisplatin) is useful in the treat-ment of hiuman malignant disease. However, its therapeutic effectiveness is limited by the appearance of severe dose-limiting toxic side-effects. These include nephrotoxicity, myelotoxicity, severe nausea and vomiting and ototoxicity. There is a great need to replace cisplatin with a less toxic derivative possessing antitumour activity at least comparable to that of cisplatin. To this end we have selected 8 platinum complexes from more than 300 derivatives previously screened for antitumour activity at the Institute of Cancer Research. These 8 compounds all possess antitumour activities comparable to or greater than that of cisplatin in several rodent tumour systems.
CLINICAL AND EXPERIMENTAL STUDIES WITH PENTAMETHYLMEL-AMINE (PMM)
The selected platinum complexes were screened against a wider spectrum of transplantable animal tumours, and against a human epidermoid carcinoma of the bronchus grown in immune-deprived mice. Toxic damage to normal tissues was assessed in the rat at maximum tolerated doses of each compound. A biochemical indicator of tissue damage, platinum-induced nuclear protein phosphorylation, was also measured in tumour and several host tissues.
Our overall conclusion from this study is that cisdiammine-1,1 -cyclobutane dicarboxylic acid (CBDCA) exhibits more selective antitumour activity than any of the other derivatives. This compound is a viable candidate for Phase I clinical evaluation, and an appropriate toxicology study is in hand. The N-dimetlhyltriazines are metabolized to selective antitumour species, and it has been proposed that the hydroxymethyl intermediates of their metabolic N-demethylation may be important for selective cytotoxicity (Hickman, 1978, Biochimie, 60, 997) . Preussman et al. (1969, Biochem. Pharmacol., 18, 1) have suggested that conjugates of hydroxymethyltriaz nes may be transport forms of biologically active species, and Kolar & Carubelli (1979, Cancer Lett., 7, 209) recently reported the isolation from rat urine of a novel 0-glucuroniside conjugate after administration of 3,3-dimethyl-1-(2,4,6-trichlorophenyl)triazene. We have now investigated the cytotoxic and antitumour properties of this conjugate. In an in vivo antitumour test against the TLX5 lymphoma in CBA/ LAC mice 50 mg/kg of the conjugate had no activity whereas 50 mg/kg of the precursor dimethyltriazene gave up to 62% increase in life span. In vitro the conjugate had no toxicity at 1 mg/ml, wNhereas the monomethyl analogue was potently cytotoxic at 50 Kg/ml. Our failure to synthesize the hydroxymethyl analogue prevented a direct comparison between this compound and its conjugate; however, p-carbomethoxy-N-hydroxymethyl-N-methylphenyltriazene was active in vivo, whereas its O-benzoylated derivative had reduced activity. The results suggest that substitution of hydroxymethyltriazines may be a deactivation step in the metabolism of dimethyltriazenes. A Phase I clinical study of dCf showed inhibition of lymphocyte adenosine deaminase (ADA) activity, lymphocytotoxicity and large elevation in erythrocyte deoxyadenosine triphosphate (dATP). The latter effect reflected increased circulating purine levels following treatment, and suggested that AdR might be used clinically to enhance dCf activity. We have previously shown that dCf potentiates the cytotoxicity of AdR in vitro (Paine et al., 1977, Br. J. Cancer, 36, 417) .
REDUCTION OF THE CYTOTOXICITY

THE TOXICITY OF BINARY COM-BINATIONS OF 2'-DEOXYCOFOR-
The underlying biochemical mechanism appeared to be via the intracellular accumulation of dATP, a known negative effector of the enzyme ribonucleotide reductase. The present study shows, however, that dCf/AdR combination can prove prohibitively toxic to normal tissues.
Treatment of mice with dCf (0-27 mg/kg) for 5 days inhibited spleen and lymphnode ADA, a 64-fold elevation of erythrocyte dATP, but no haematological toxicity or weight loss. However, if mice were injected with AdR (270 mg/kg) in combination with dCf, weight loss, haematological toxicity and liver damage occurred. Leucopenia was pronounced, often with agranulocytosis. The femoral marrows of these mice showed cytotoxic damage, including vacuolation and some giant metamyelocytes. Erythrocyte dATP levels were raised 1500-fold. Mortality during treatment was attributable to acute liver failure; marrowr toxicity was only detected when treatment had finished. No such toxic effects were seen in mice receiving adenosine (AR, 270 mg/kg) in combination with dCf, AR alone, or AdR alone. We conclude that the supplementation of clinical dCf schedules with AdR should be considered with caution.
THE EFFECTS OF NANDROLONE DECANOATE (DECA -DURABOLIN, ORGANON) ON THE TOXICITY AND ANTI-TUMOUR ACTION OF CCNU IN EXPERIMENTAL MOUSE COLON TUMOURS. J. A. DOUBLE & M. C. BIBBY, Postgraduate School of Studies in Medical and Surgical Sciences, University of Bradford
There are conflicting reports in the literature on the value of anabolic steroids in the management of patients undergoing cancer chemotherapy. This situation almost certainly arises from variation in dose and treatment schedules. Most reports describe simultaneous treatment with low doses of anabolics, which appear to be of no value. The Bradford group have maintained that in order to achieve clinical benefits it is necessary to pretreat the patients with high doses of anabolics (Hancock et al., 1977, Br. J. Surg., 64, 134) . Clinically, nandrolone decanoate (N.D.) appears to reduce the toxicity of various cytotoxic agents. The present study is an attempt to transfer a clinical impression to numerical data, using an experimental model system. The spectrum of chemotherapeutic sensitivity to standard agents of the mouse adenocarcinoma of the colon (MAC) system has been shown to be similar to human large-bowel cancer (Double & Ball, 1975 , Cancer Chemother. Rep., 59, 1083 . Therapeutic indices are low and responses are only seen close to maximum tolerated dose. We have shown that 7-day pretreatment with N.D. raises the LD50 of CCNU from 78 mg/kg to 112 mg/kg. It could be argued that this was a generalized reduction in the potency of the cytotoxic agent. Results from combined toxicity and antitumour studies using the MAC 13 line and CCNU however have shown that the antitumour action of the cytotoxic agent is unaltered by the presence of N.D. Simultaneous treatment writh N.D. and CCNU produces a therapeutic index of 1-1, wlhereas 7-day pretreatment with N.D. before CCNU produces a therapeutic index of 1-7. Further studies on this phenomenon are under way using other agents and other tumour lines. Prednisolone enhances the selectivity of chlorambucil by reducing its systemic toxicity and enhancing tumour-cell kill (Harrap et al., 1977, Eur. J. Cancer, 13, 873) . The present studies demonstrate that although prednisolone does not enhance the overall macromolecular binding of 3H-chlorambucil in vivo, it does modify its binding to specific chromatin fractions in a tissue-selective manner. Binding was increased in chromatin fractions of both alkylating-agent sensitive and resistent strains of Walker 256 carcinosarcoma, but reduced in the corresponding fractions from intestinal mucosa. In vitro, prednisolone enhanced the binding of i4C-mephalan to soluble chromatin in resistant cells, but did not alter gross macromolecular binding. The highest concentration of bound drug was in the insoluble chromatin fraction. About 30%O of chromatin-bound drug was released after DNase II digestion. Chlorambucil treatment enhanced the digestion of chromatin by micrococcal nuclease, as demonstrated by sucrose-density-gradient fractionation. Chlorambucil appeared to bind preferentially to internucleosome chromatin.
EFFECT OF PREDNISOLONE ON
These data demonstrate that the enhanced selectivity of clhlorambucil in the presence of prednisolone is associated with tissue-specific modulations of chromatin binding, and that internucleosome linker regions and insoluble structural chromatin are major alkylatingagent-binding sites.
CYTOSINE ARABINOSIDE (ARA-C) DEAMINATION Ara-C is an effective drug ill acute myeloid leukaemia (AML). Used alone remission occurs in only 25-470/0 of patients (Armentrout & Burns, 1974, Am. J. MIed. Sci., 268, 163) . Ara-C is converted intracellularly to its active metabolite Ara-CTP in AML myeloblasts, and also deaminated to Ara-U, an inactive metabolite. High deaminase activity in lysed marrow blasts has been associated writh clinical resistance to Ara-C (Steuart & Burke, 1971, Nature (New Biol.) , 233, 109) but this was not found with intact peripheral blasts (Smyth et al., 1976, Eur. J. Cancer, 12, 567) . Intact marrowr myeloblasts from 11 patients w,ith newly diagnosed untreated AML were incubated w%ith (3H)-Ara-C (1 nM-100 [kM) for 45 min at 37°C in Eagle's medium.(3H)-Ara-CTP and (3H)-Ara-U production was measured, with and without 1mM tetrahydrouridine (THU) a potent deminase inhibitor. The sensitivity of DNA synthesis to Ara-C was measured using inhibition of (3H)-TdR incorporation into DNA by 10nM-10jtM unlabelled Ara-C, incubated under identical conditions (+ THU). The ratios of Ara-U/ Ara-CTP ranged from 0-32 to 19-11. THU increased Ara-CTP production by 0-27 0 and deamination was completely inhibited. The increase in Ara-CTP was not related to Ara-U/Ara-CTP ratio, but to 0/ deamination of medium in absence of THU . 500o inhibition of DNA synthesis was produced by 30-100nM Ara-C, and at 1 ,uM 800O inhibition occurred in all blasts.
THU did not increase the sensitivity to Ara-C.
These results show that Ara-C was freely available to both metabolic pathways, and that deainination does not produce resistance to Ara-C by diverting Ara-C intracellularly from the kinase pathway that produces Ara-CTP. (CB 3717 Critical examination of the folate enzyme network suggests the need for a folate inhibitor of thymidylate synthetase (TS) which should give an antimetabolite superior both to methotrexate (MTX) and to 5-fluorouracil (FU) for the following reasons: (i) TS is the rate-limiting enzyme in the thymidylate cycle; (ii) the antipurine effect of MTX, causing gut toxicity in mice but contributing little to the antitumour effect, is avoided (Harrap et al., 1977, Chem. Biol. Interact., 18, 119) ; (iii) a folate analogue does not require metabolic activation; resistance to FU is frequently due to the deletion of its activating kinase; (iv) unlike FU, there should be no incorporation into RNA with an associated toxicity; (v) the competing metabolite, 5,10-methylene-tetrahydrofolate, lies at a metabolic branch point and might not build up to overcome the block; (vi) Having a different locus of action from MTX the agent should be active against MTX-resistant cells which have raised intracellular dihydrofolate reductase.
THE DESIGN AND SYNTHESIS OF
We have achieved this aim, and report here the design and synthesis of 2 new 2-amino-4-hydroxy-quinazoline antifolates. Progressive unsaturation of the terminal C-C bond of a 3-carbon substituent at N-10 increases the affinity of the compounds for TS. The 5000 inhibitory concentrations were: 170nM (propyl); 69nM (allyl); 5nM (propargyl). This last named, CB 3717, is the most potent inhibitor of TS yet described. Some of its biochemical and antitumour properties are outlined in the next paper. 
BIOLOGICAL PROPERTIES OF
propane] is a non-selective inhibitor of mitosis (Bakowski, 1976, Cancer Treat. Rev., 3, 95) . It is active by mouth and soluble in dilute HCI. To investigate whether gastric acidity had any influence on the subsequent fate and activity of the compound on experimental tumours, cimetidine was given in anticipation that the antitumour effect of razoxane would be appreciably diminislhed. In the event the opposite occurred.
Female Sprague-Dawley rats were inoculated with Walker carcinosarcoma and pretreated with cimetidine 1 h before administration of razoxane. The antitumour effect of razoxane in these rats was significantly greater than in those treated with razoxane alone (P < 005). Cimetidine alone possessed no significant antitumour activity. The experiments have been repeated 4 times and the results have been similar on each occasion.
It is clear therefore that gastric acidity is not important to the antimitotic activity of razoxane. Whether the enhanced activity of razoxane after cimetidine might be due to increased blood levels of razoxane or other mechanisms is not yet resolved. (Harrap et al., 1977, Chem.-Biol. Interactions, 18, 119) . 32 patients were treated in a Phase I clinical study of ITA rescue. Initially ITA, without MTX, was given to 9 patients. Then 400 mg/ m2/24 h MTX was infused into 17 patients and ITA, in decreasing doses, was given at the end of these infusions. A 'minimum safe rescue" was identified. In 6 patients the dose of MTX w%as then increased in stages to 1-5 g/ m2/24 h.
No toxicity was seen with ITA alone, nor when MTX 400 mg/M2/24 h was followed by rescue infusions of more than: inosine 0-2 g/ m2/24 h, TdR 1 g/m2/24 h and allopurinol 200 mg 8-hourly. Below this 'minimum safe rescue", myelosuppression, mucositis and skin rashes were seen, even though rescue was continued until circulating MTX had fallen to 6 x 10-8M. With 800 mg/m2/24 h MTX '*minimum safe rescue" was successful, but when MTX 1P5 g/m2/24 h was used, toxicity occurred in spite of rescue. MTXrelated skin lesions were more frequent than would be expected with the MTX plasma levels achieved. This study showed that ITA is not in itself toxic and the "minimum safe rescue" is effective from MTX doses up to at least 800 Circulating levels of nucleosides and bases were measured in patients' plasmas, and in samples from healthy human volunteers. Patients' pretreatment levels of hypoxanthine (HX) fell into 2 distinct groups: the majority (20/25) were in the range 0-85-6-5 )uM, but 5/25 ranged between 49 8 and 64-2 [kM (mean 52-4 + 2.3). The "low" HX group (mean 2-62 + 0-32 MM) had significantly higher levels of circulating HX (P = 0.006) than healthy humans (1-62 + 0 2 tkM). Following its oral administration, Ap was rapidly metabolized to oxypurinol, which circulated at high levels ( 10-4M) for considerable periods ( > 6 h). During the administration of the "minimum safe rescue" of ITA, no significant elevation of HX, thymine (T) or TdR was observed. At higher rescue doses TdR was metabolized to T with a half-life of 14-20 min; HX possessed a half-life of 40-65 min.
The method has a high sensitivity; it has also been applied to enzyme assays (e.g. xanthine oxidase, dihydrothymine dehydrogenase) and to the purification of labile radioactive materials. Lectin affinity and immunoadsorbent chromatography were used to purify papainsolubilized tumour-specific antigens (TSA) from the aminoazo dye-induced rat hepatoma D23. Isolated antigens were radioiodinated using procedures which included (a) coupling of 1251-labelled tyrosine to TSA with a carbodiimided reagent, (b) protection of antigenic determinant by labelling TSA while bound to its syngeneic immunoadsorbent. These radiolabelled antigens retained serological activity, as demonstrated by coprecipitation (double antibody) tests and specific rebinding to syngeneic immunoadsorbents. Immunoadsorption chromatography indicated that one consequence of radio-labelling hepatoma D23 TSA with 1251 was to reduce the affinity of the labelled antigen for its syngeneic specific antibody. The modified capillary-tube leucocyte adherence inhibition (LAI) assay (Ballard & Dickinson, 1980, Clin. Exp. Immrunol., 40) has been used to monitor host immune response to a transplantable mammary carcinoma of spontaneous origin in the rat (Moore & Dixon, 1977, Cell Tissue Kinet, 10, 583 Table) . Activation was associated with macrophages sedimenting at 5-9 mm/h, whilst those sedimenting at 1-5 mm/h were less activated and contained a higher proportion of peroxidase-positive cells.
DETECTION OF RADIOIODINATED
The sedimentation profile of EA-rosetteforming cells within cell suspensions prepared from the immunogenic fibrosarcoma FSA-R was identical to the profile of peritonealexudate cells, and isolation of tumourinfiltrating macrophages indicated at least 2 sub-populations.
Comparison of tumour macrophages with peritoneal macrophages indicates that the highly activated, rapidly sedimenting fraction is in the same state of activation as corresponding Corynebacterium parvum-activated macrophages, and both are more highly activated than proteose/peptone-elicited macrophages. The less rapidly sedimenting tumour-macrophage fraction was more highly activated than the corresponding C. parvum fraction, which was in turn more activated than proteose/peptone-elicited macrophages. Only after treatment of sections with 0-1 00 trypsin for 2 h was it possible to demonstrate tumour-cell staining in sections from 15/27 lung-cancer patients. Of 11 patients who had raised serum CEA levels (> 40 ng/ml) preoperatively, 9 were positive; of 10 who developed raised levels postoperatively, 4 were positive; of 6 who had normal levels throughout follow-up, 2 were positive. Although an absorbed non-immune sheep Ig did not stain tumour cells after 2h trypsinization, both this, and the absorbed anti-CEA Ig, showed considerable staining of collagen. As little is known of the effect of trypsin on antigenic determinants in tissue sections, these preliminary results must be treated with caution. However, they illustrate the problems of working with a highly absorbed anti-CEA Ig, and raise the possibility that some reports of anti-CEA localization in vitro in lung tumours may be due to specific anti-NCA antibodies, or antibodies directed at antigenic determinants common to both CEA and NCA. (Dykes et al., 1980, Br. Med. J., i, 220) . Using indirect immunofluorescent and immunoperoxidase techniques, the same Ig shows surface and cytoplasmic localization with cells from a human anaplastic lungtumour line (Calu-6). A temporal variation exists with the proportion of cells staining in the immunofluorescence test, being highest in the lag phase of culture growth and decreasing during the log phase.
In a 51Cr-release assay, the same Ig is cytotoxic to Calu-6 target cells used immediately after trypsinization, when 20% of cells show localization of the Ig. This effect is augmented by the addition of rabbit complement, but abolished by prior heat inactivation of the Ig (56°C, 30 min).
Although vincristine exhibits no immediate lysis, in the presence of heat-inactivated Ig or heat-inactivated Ig and complement its cytotoxicity is greatly increased and apparently dose-dependent. Similar effects with adriamycin, 5-fluorouracil, bleomycin and methotrexate have not been obtained.
The specificity of these interactions is under investigation. Results indicated that irradiation enhanced cytotoxicity of the drugs in all cases, but the most dramatic effect was elicited by the azidosulphonamide (4) which was non-cytotoxic in the dark bu significantly cytotoxic when incubated with L-1210 cells in light. Pre-irradiation of the azidosulphonamide solution before exposure to L-1210 cells abolished activity (IDgo> 1 x 103 [g). In control experiments the stable photoproducts formed from azidosulphonamide were found to be non-cytotoxic, and it is possible that a photogenerated nitrene species is the destructive agent. (Workman, 1979, Br. J. Cancer, 40, 335) have shown that pretreatment of mice with phenobarbitone or phenytoin increased the acute LD50 of the hypoxic cell radiosensitizer misonidazole (Ro 07-0582; MISO). The mechanism involves an increased rate of metabolism to desmethylmisonidazole (Ro 05-9963; DEMISO) through induction of hepatic microsomal enzymes, which decreases the area under the curve (AUC) for MISO in blood and brain. Clinical studies are in progress to assess the possible role of plienobarbitone and phenytoin, and also the corticosteroid dexamethasone, in reducing MISO neurotoxicity.
BIOLOGICAL ACTIVITY OF MONO-CLONAL ANTIBODY TO
EFFECTS OF DEXAMETHASONE ON
Experiments were carried out to investigate the interaction between dexamethasone sodium phosphate (DEX) and MISO in C3H mice. MISO was injected i.p. at a dose of 1 g/kg and MISO and DEMISO w-ere measured in blood and brain by high-performance liquid chromatography (Workman et al., 1978, J. Chromatogr., 147, 507) . Pretreatment with DEX (0.5, 25 and 100 mg/kg i.p. daily for 5 days) had no effect on the metabolism, pharmacokinetics and urinary excretion of MISO. Simultaneously administered DEX (25 mg/kg i.v.) did not alter the blood concentrations of MISO and DE1MISO, but did reduce the brain MISO AUC by 1500 (P <0-02).
Simultaneous DEX did not change the acute LD50 for MISO ( 1 -1 9 g/kg). However, this was reduced to 1-7 g/kg after pretreatment with 0-5 mg/kg/day DEX, and decreased further at the higher doses of DEX. (1977, Cancer Res., 37, 3639). These lines include the EMT6 and RIF-1 mouse tumours and the HT29 and CaMa-1 human colon and breast carcinomas. Response of the growing spheroids to cytotoxic drug treatment in vitro has been studied using both spheroid growth delay and clonogenic cell survival as endpoints. In EMT6 spheroids, time of assay after drug treatment was an important parameter in the determination of cell survival. Apparent recovery from potentially lethal damage occurred after treatment with nitrogen mustard (NH2), BCNU, CCNU, myleran and cis-platinum. For this group of agents a reasonably similar relationship was found between spheroid growth delay and cell survival (measured 24 h after treatment). For adriamycin, actinomycin D and 5 fluorourcil, however, extended grow%th delay was observed w%ith relatively little cell kill. The human cell spheroids were similar to EMT6 in sensitivity to HN2 (as assayed by growth delay) but markedly less sensitive to BCNU. The relationship betwreen spheroid growtth delay and cell survival in RIF-1 and HT29 spheroids is currently being investigated.
DRUG INTERACTIONS WITH MISON
Many features of the tumour spheroid model system make it amenable to the investigation of tumour-response parameters in a wvay that cannot be done with simpler monolayer cultures. 10 ,ug/ml BLM for 1 h at 37°C is increased to 3 05 days at 43°C. Heat alone under these conditions produces a growth delay of 0 50 days. Preheating at 40°C has previously been shown to alter the response to EMT6 cells to subsequent heat and drug exposures. Similarly with spheroids, a prior exposure of 6 h at 40°C induces tolerance to subsequent BLM (20 ,ug/ml) at 43°C/1 h, reducing the growth delay from 5-95 days to 3 70 days. With adriamycin, no increased cytotoxicity was seen after a lh exposure at 43°C. However, prolonged exposure (6 h) to 1 ,ug/ml adriamycin increased the growth delay from 1-10 days at 37°C to 4-15 days at 42°C. Current investigations into the heat and drug sensitivities of spheroids pretreated with 5mM MISO at 37°C under both oxic and hypoxic conditions were also reported. Blood flow in the Yoshida sarcoma (meassured by rubidium-86) was inhibited by 90-10000 at high blood-glucose levels (>20mM). A similar finding was obtained in MC-7 sarcoma and D-23 carcinoma. The inhibition in each tumour was independent of site, occurring in s.c. tumours on the foot and flank and in i.m. leg tumours, and was similar at a range of tumour volumes. A similar inhibition was produced by galactose, a sugar not metabolized by the tumours. In the i.m. VX2 carcinoma in the rabbit, blood flow was also inhibited by hyperglycaemia. Blood flow in normal tissues of the animals was little affected by hyperglycaemia.
EFFECT OF HIGH BLOOD-SUGAR
The inhibition of blood flow enhanced the specificity of thermotherapy; the tumour was unable to dissipate heat via circulatory blood, whilst normal tissues were cooled by a heatinduced increase in blood flow which was unaltered by the increase in blood sugar. Tumour heating was more uniform at high sugar levels and the use of such conditions, combined with heat, may eliminate the incidence of "cool zones" around tumour blood vessels.
If inhibition of blood flow at high bloodsugar level proves a general phenomenon in tumours, it may represent an Achilles' heel for selective therapy in cancer cells isolated from the host. Most laser-based flow cytometers lack fluorescence excitation versatility, due to the limited number of lasing lines that can be obtained with a single laser. Even with a large tunable laser only one wavelength can be obtained at a time, which considerably reduced the potential of such instruments. These problems have been overcome in our unit by the design and construction of a flow cytometer with a small argon laser emitting blue light at 488 nm, which is used in conjunction w-ith a large krypton laser. The latter can be tuned to emit in the UV, violet, green, yellow or red and any one of these lines can be used for excitation either sequentially or simultaneously w%%ith the blue line from the argon laser. Narrow-angle forward light scatter at two wavelengths, plus 900 light collection and analysis in the UV, violet/low blue, high blue, green and red wavelength bands can be achieved simultaneously givsing 7-parameter analysis. The principles of operation, design specifications and preliminary performance data wAere described. Four patients with advanced breast cancer were treated with a 72h continuous infusion hydroxyurea (HU) at 6-12 g/day. Biopsy specimens of marrow, skin and tumour were taken before the infusion was begun and again at 72, 78 and 84 h. The [3H]-TdRlabelling index (LI) of these specimens was determined by the method of Meyer & Bauer (1975) with ARG for 10 days, and in addition the S-phase proportion of the marrow was determined by flow cytofluorimetry after nuclear staining with propidium iodide. In patients in whom adequate serum levels of HU were sustained (>01mM), the LI of the marrow was reduced by the infusion from a pretreatment level of 7-15% (mean 12%) to 2-6% (mean 4.50/) at 72 h. After the infusion wNas discontinued a rebound phenomenon was seen with a marrow LI at 78 h of 12-25% (mean 20%) and at 84 h of 15-22°o (mean 1850 ). Similar values for the S-phase proportion were obtained by cytofluorimetry. The pretreatment LI of the skin specimens was 1 0-255% (mean 1 60°) and at 72 h it was reduced to 0-2-0-6% (mean 040o) and again a rebound was seen at 78 h (LI 2-5-14%, mean 6.2%) and at 84 h (LI 15-22%, mean 180/). The tumour specimens, however, showAed little perturbation, the pretreatment LI was 4-7-160/o (mean 10%), at 72 h 9-1600 (mean 12%), and at 78 h 9-220/ (mean 15%). Individual tumours contain different proportions of non-neoplastic cells. Some of these are stromal, whilst others possibly have a protective function, mediated immunologically or otherwise. It has previously been reported that transplantable tumours of high metastatic potential contain fewer macrophages than ones incapable of dissemination. However, the processes of tumour transplantation and of maintaining tumours in culture probably alter their properties, and we have therefore chosen to re-examine the relationship of macrophage content to tumour spread, using primary mammary tumours in mice.
CIRCULATING
MEASUREMENT OF LECTIN BIND-
Ingestion of latex particles proved too nonspecific for reliably identifying macrophages in tumour-cell suspensions, and histochemical staining for enzymes such as lysosome, acid phosphatase and nonspecific esterase proved even more limited in value. We therefore used the Fe-mediated phagocytosis assay, in which antibody-coated sheep red cells are ingested by the macrophages under controlled conditions, to quantitate tumour macrophage content expressed as a proportion of total cells in the tumour suspension. With this we found moderate variation between tumours, both in the proportion of macrophages and in their phagocytic capacity.
The metastatic colonization potential of the tumours was assayed by necropsy of mice 90 days after i.v. inoculation of the disaggregated tumour cells, and the results for individual tumours was correlated with their macrophage content at the time of inoculation. It was found that there is no correlation between macrophage content and the colonization potential of these primary tumours. The accretion of platelets has been postulated to facilitate the seeding of metastatic tumour cells. To test whether this hypothesis applied to the TLX-5 murine lymphoma, the occurrence of blood-borne metastases was mimicked by injecting a low number (1-5 x 102) of TLX-5 lymphoma cells i.v. Tumour spread was not confined to the first vascular bed encountered, the lungs, but was also evident in liver, kidney and spleen. An attempt to prevent the seeding of injected lymphoma cells was made by injecting an inhibitor of platelet function, RA233 (30 mg/ kg) i.v. 3 min before the lymphoma cells. This procedure had no effect on the survival time of tumour-bearing mice, which were all dead within 12 days regardless of treatment.
EFFECT OF INHIBITION OF PLATE-
In To obtain a high-metastasis variant the procedure was repeated substituting cells from lung tumours. The latent and the growth periods increased with each generation, and by the second passage differed significantly from those of the control group, indicating a slower primary tumour growth rate with each successive generation. The number and size of metastases increased after the first passage (75 + 10 compared to 55 + 1 for stable line (P <0 01)). In both lines primary tumours contained more tumour cells and less macrophages than metastases, but the high-metastasis varient contained fewer macrophages at both sites than the stable line. This suggests a lowered immune response to the variant.
Low-metastasis variants were obtained by adapting cells to monolayer culture. Only a few tumour cells survived to form established cultures, and these were reinjected into mice. The latent and the growth periods increased substantially, and there were fewer metastases in the lungs. However, cells of metastatic origin produced significantly more metastases (22 + 4) than primary cells (9 + 4) (P < 0 05). In previous studies on primary mammary tumours we found that cells from some could heavily colonize the lungs after i.v. inoculation in mice, whereas those from others did so weakly or not at all. The tumours were all adenocarcinomas and we could find no features which correlated with this behavioural variation. However, the high reproducibility of the findings in each batch of animals inoculated with a given tumour indicated that the differences between individual tumours were due to intrinsic differences in their constituent cells. The levels of serum 32-microglobulin (:2-m) were measured serially in 36 patients with multiple myeloma for 6 moniths to 5 years. The initial :2-m levels are highly correlated to survival (P=0 01). The median survival in months, according to the initial ,82-m levels (number of patients in parentheses) -was as follows: >6 mg/l, 14 months (11); 3-6 mg/I, 19 months (12) and <3 mg/l, >50 months (13). These levels of :2-m are correlated to tumour mass as calculated from multifactorial indices. An initial :2-m of >3 mg/l tended to fall on treatment but rarely reached normal, a rising value usually heralded an irreversible progression, and when > 8 mg/l, often accompanied by renal failure. The level of < 3 mg/l was usually associated with a relatively benign evolution but carried an increased risk of infection. radiological evidence of respiratory-tract infection. Twenty-five patients were receiving antibiotics at the time of TTA (Tobramycin and Cephazolin 14, Tobramycin and Flucloxacillin 5, other combinations 6). A 14-gauge Davol IVI catheter was inserted under sterile conditions through the crico-thyroid membrane. Bronchial secretions were aspirated, with or without lavage with 10 ml of normal saline, and specimens were cultured immediately. The procedure was carried out under platelet cover if indi-cated, and no serious haemorrhagic complications were seen. Minor surgical emphysema occurred in one patient. There was no radiological evidence of pneumothorax. Positive cultures w,%ere obtained from TTAs (46%). In these 16 cases, concurrent sputum examination was positive to culture in only 4, negative in 5, and unobtainable in 7. There was no case in which the TTA was negative and the sputum positive. The TTA was positive in 16/30 cases in which the chest radiograph was abnormal. 12 cases in whom the TTA was positive were receiving broad-spectrum antibiotics and in 8 of these the regimen was altered. In the 4 positive cases not an antibiotics, the findings influenced the choice of drugs. The high diagnostic yield of this simple test suggests that its routine use in the diagnosis of chest infection in neutropenic patients should be further evaluated. 
London
The relationship of fatal infection to neutropenia during remission induction for AML is analysed. 150 consecutive patients received repeated cycles of Adriamycin (ADR) Cytosine Arabinoside (Ara-C), Vincristine and Prednisolone given over 9 days (Regimen 1), or ADR, Ara-C and Thioguanine given over 5 days, at either high (Regimen 2) or very high doses (Regimen 3). The table shows the number of pts and fatal infections and the mean duration of neutropenia in days, associated with the first 2 treatment cycles, when all the infective deaths occurred. The duration of neutropenia was longest in Regimen 1 (possibly because treatment was given over 9 days) and was virtually identical in Regimens 2 and 3. However, there was a significantly higher incidence of fatal infection 13 in the more intensively treated group (Regimen 2 vs 3, P<005). 22/34 fatal infections were preceded by profound neutropenia (neutrophils <041 x 10q/l) for a mean of 8 days. 27 of these 34 pts showed no rise in neutrophil count in response to infection. The data confirm that fatal infections are associated with persistant severe neutropenia. Initensification of therapy, resulting in a significant increase in fatal infections, did not increase the degree or duration of neutropenia, suggesting that other factors, such as mucosal ulceration significantly contribute to outcome. A boy aged 7 years when ALL was diagnosed, had a first marrow relapse 4 years later. This was followed by a good second remission of 18 months. The patient died in second relapse 6 years after diganosis. On marrow morphology and cytochemistry the cells in the 3 disease episodes were indistinguishable. The chromosome constitution of all marrow cells at diagnosis was 47 XX, del(5)(q13)del (15)(q15) RIA in these 2 patients gave similar concentrations to HPLC, it has consistently overestimated drug excretion in a larger patient series, due to interference from 2 4-diamino N10-methylpteroic acid. It was not possible to determine MTX accurately in bile by RIA because of marked quenching. It was, however, readily identifiable by HPLC, peak concentrations being reached 0 5-3 h after drug administration. Decay of drug in bile was biphasic, with a mean terminal half-life of 15 h. The biliary concentration always exceeded that in serum, with a maximum bile:serum ratio of 100:1. Cumulative biliary excretion could only be determined in one patient, where 13% of the administered dose was excreted in 48 h. Although moderate-dose MTX is said not to be metabolized, 7,OH-MTX was identified in all 3 constituents. Only small amounts were present in bile in contrast to serum where substantial amounts may be present 24 h after administration. This study confirms that the renal route is the main excretory pathway for MTX, and on the basis of these observations dose reduction is probably not necessary in the presence of obstructive jaundice. These findings led to BLM monitoring in all patients given the drug by the intrapleural or i.p. routes. Systemic peak concentrations of BLM showed a 5-to 10-fold increase in some cases, and one of the patients who died had normal plasma concentrations of BLM during a previous infusion with the same dose schedules. In a further 5 patients studied who had low toxicity, the systemic BLM concentration was 4000 of that when equivalent amounts were given by the i.v. route (Stuart et al., 1979, Br. J. Cancer, 40, 316) .
CYTOGENETIC EVIDENCE FOR
PHARMACOKINETICS OF CYCLO-
In a further 4 patients a predictive dose of 5 mg BLM was given, followed by the appropriate higher dose 4-5 h later. The mechanism of BLM toxicity associated with these levels of intracavitary drug is unclear, but it seems reasonable to continue to monitor BLM during intracavitary thei apy. Alkylating agents form an important class of environmental carcinogens, in addition to being widelv used as anti-cancer agents. In vivo exposure to alkylating agents leads to the formation of 8-alkylcysteine and Nalkylhistidine derivatives in haemoglobin. Methods have been developed for the quantitation of these amino acids in rat or human haemoglobin, using capillary gas chromatography-chemical ionization--mass spectrometry. After treatment of rats with the methylating agent methyl methanesulphonate (MSS) the amount of S-methylcysteine in haemoglobin bears a linear relationship with the dose of MMS injected. In contrast, the degree of methylation after injection of the anti-cancer drug 5-(3,3-dimethyl-1-triazene)-imidazole-4-carboxamide (DTIC) is very low. Hydroxyethylhistidine has been determined in the haemoglobin (after sodium borohydride reduction) of humans exposed to vinyl chloride. The biological response of animals to BBN is affected by species (Hirose et al., 1976, Gann, 67, 175) , strain (Moon, unpublished) and sex (Bertram & Craig, 1972, Eur. J. Cancer, 8, 587) . It is an organ-specific bladder carcinogen for the rat, and we also find it to be a powerful bladder carcinogen for the hamster but ineffective in the baboon (Hicks et al., unpublished) . In the Fischer 344 rat, BBN produces multi-focal, large, exophytic, welldifferentiated, transitional-cell tumours with some squamous metaplasia, which generally do not metastasize but slowly invade the bladder wall. Their histopathology and ultrastructure are comparable to low-grade, superficial, papillary bladder cancers in man which are often regarded as relatively benign. Nevertheless the survival of these animals is related to the BBN dose and the tumours cause death by obstruction and haemorrhage. The dose-response to BBN is measured in terms of total tumour volume produced with time and is reffected by the life tables. The BBN/Fischer rat system has been used in many laboratories to induce bladder tumours for chemotherapeutic trials and other investigations. Its suitability as a model for human bladder cancer is limited to the local disease only, and it cannot be used to study meta- , 1962, Natare, 196, 180) . They have been designated malignant lymphoma of histiocytic type (Wagner, 1976, J. Natl Cancer Inst., 57, 509 ) and the rate is 40%. In 2 other strains of rats the rate was 5 and 7 0 (Wagner, submitted for publication) and it also varied with the type of silica injected (Wagner, submitted for publication). The tumours were not found after injection with saline, coal or carbon (Wagner, 1976) . Lymphocytic lymphosarcoma occurred equally in saline-and silica-injected rats. Electron microscopy and role of thymectonmy are discussed, and the importance of the production of a lymphoma consequent upon the introduction of an agent believed to be specifically cytotoxic to macrophages (Allison, 1976 , In Vitro Methods in Cell-Mediated Tumour Inmunity, p. 395). Although numerous experiments have been performed with quartz during the last 50 years, this is the only study in which this mineral has been shown to be associated with malignancy. The development of bladder tumours in the urinary bladder of the F344 rat in response to BBN is dose-related. Thus 12 months after dosing with 300, 600 or 1200 mg BBN the total tumour volumes were 7,380 and 2200 mm3 respectively. To avoid killing animals in order to detect the tumours histologically, the possibility was investigated of measuring urine parameters as indicators of tumour growth. Haematuria was found to parallel tumour growth. The correlation between tumour size and haematuria was demonstrated for individual animals after different doses of BBN and the sensitivity of the method discussed. In general, the method is reliable for the detection of tumours over 40 mm3 in size, but a number of false negatives were obtained with very small tumours. Haemorrhagic anaemia was found to be associated with the presence of large bladder tumours. Examination of urine sediments of 62 animals by urine cytology gave an 80°/, correct correlation with bladder pathology as found at subsequent necropsy. The 6 false negatives were not correlated with tumour size but all had heavy fungal contamination preventing accurate diagnosis. Thus while neither technique alone is entirely reliable, we have found that together they provide a useful way of monitoring the progress of animals in bladder carcinogenesis trials. N-nitrosomethylurea (NMU) has been reported to induce mammary tumours in rats, with a high incidence of metastasis to marrow and spleen and the development of hypercalcaemia (Gullino et al., 1975, J. Natl Cancer Inst., 54, 401) . In our hands i.v. NMU to 50-55-day-old rats induced mammary tumours in 78% of F344/N and 91% of ICRF Wistar females. Mean latent period for F344/N rats was 149 days and for ICRF Wistar rats was 93 days. 98 % of mammary tumours were classified histologically as adenocarcinomas. Primary tumours of nonmammary origin were detected at low incidence. These were squamous-cell carcinomas in the peri-urethral and auditory regions, adenocarcinomas of the bronchus, endometrium and colon, primitive neural ectodermal tumours of the brain and disseminated lymphoma/leukaemia. No histological evidence was found for metastases of either the mammary tumours or other primary tumours in lungs, femora, vertebrae, liver, kidneys, spleen, brain or adrenals, and plasma calcium measurements varied within the normal range independently of tumour volume. No histological difference was found between NMU-and DMBA-induced mammary adenocarcinomas. Oophorectomy at the time of NMU administration greatly inhibited tumour induction; oophorectomy when at least one tumour per animal was palpable produced growth delay or regression in all cases, with subsequent tumour re-growth in 7/8 animals. All NMU-and DMBA-induced mammary tumours tested contained cytoplasmic oestrogein receptor at similar concentrations. No evidence for tumour-induced hypercalcaemia was found. In view of the inability of these tumours to metastasize and/ or cause hypercalcaemia the NMU model of breast cancer offers little advantage over other hormonally responsive models. (Williamson et al., 1979 , Gastroenterology, 76, 1386 . Using male Fischer rats (n=205) susceptibility to cancer was studied in colon re-exposed to the faecal stream 4 weeks after defunctioning transverse colostomy. Other groups had laparotomy alone, permanent colostomy, or colonic transection repeated after 4 weeks. Tumours were induced by 1,2-diemthylhydrazine (300 mg/kg) in divided s.c. doses over 11 weeks, starting 2 days after the second operation.
ESTIMATION OF EXPOSURE TO AL-KYLATING AGENTS USING GAS
BIOGENESIS OF BLADDER CANCER
DETECTION OF BBN -INDUCED BLADDER TUMOURS BY MEASURE-
CHARACTERISTICS OF N-NITROSO-
In distal colon, amounts of RNA, DNA and protein fell by 53-5800 4 weeks after transverse colostomy (P<0-001), but returned to normal within 1 week of colostomy closure. This reactive hyperplasia promoted the development of distal tumours, as compared with repeated colonic transection (incidence 32% vs 60/,: P<0-03). In proximal colon, protein and nucleic acid contents were unaltered by transverse colostomy, but were increased by 18-590 4 w,eeks after restoration of intestinal continuity (P=0 05-0 002); tumour yields were unchanged, however. Suture-line tumours were commoner after repeated transection than after colostomy closure (760% vs 39 o: P<0-01). The presence of a permanent colostomy did not affect the number of distal tumours, but 260/ of these animals developed cancers at the stoma. Hypoplasia is confined to the distal colon after transverse colostomy, but it occurs in both proximal and distal colon after colostomy closure. Intense adaptive hyperplasia promotes carcinogenesis in the distal colon. The presence of virus-specific RNA has been investigated by the technique of in situ hybridization using 7 5dum sections of human normal and neoplastic cervical tissue. The 125I-labelled DNA probes used were from herpes simplex virus 2 (HSV2), adenovirus types 2 and 5, and bacteriophage A. Results were assessed by counting grains within a standard area. A positive result was considered to be a value at least twice the grain count for control sections, in at least 2 of the 4 consecutive serial sections on each slide.
DETECTION OF HERPESVIRUS-
No positive hybridization was found for the adenovirus and bacteriophage probes against neoplastic and benign cervical tissue. But HSV2 probe produced positive hybridization for all 11 biopsies from cervical intraepithelial neoplasia, for 14/17 squamous-cell cervical carcinomas, for 1/9 cervical adenocarcinomas, and 1/10 biopsy samples of benign epithelium. Surface swabs of the cervix taken from the one case of adenocarcinoma positive for hybridization were positive for free virus; all other swabs were negative. The ability of a number of normal and neoplastic cell lines to survive and grow in culture medium in which methionine was replaced by its immediate precursor homocysteine has been studied. None of the tumour lines showed optimal growth under such nutritional conditions, although there was a variability in the ability to survive and grow. In contrast the normal cell lines studied showed optimal growth in media containing homocysteine only. Although homocysteine alone was unable to support growth of tumour cells, it did stimulate growth under conditions in which methionine became growth-limiting. A correlation has been obtained between the ability of a cell line to survive in media in which homocysteine substitutes for methionine and the minimal concentration of methionine required for optimal growth. Thus normal cell lines grow optimally in media containing only 05 Htg/ml of methionine in the presence of homocysteine, whereas some of the tumour cell lines require a concentration of methionine greater than 2 jtg/ml. This suggests that the inability of tumour cell lines to survive in methioninedepleted, homocysteine-supplemented media is not due to any intrinsic biochemical defect, but to the higher methionine requirement of such cells. The establishment of a relationship between alimentary cancer in cattle and various putative carcinogens (e.g. bracken, viruses) and anecdotal evidence of alimentary cancer in both humans and animals living in close proximity, suggested an investigation with implications for human cancer. Consequently a population-based study of the geographical distribution of human cancer was carried out in Argyll in S.W. Scotland where the occurrence of bracken is high, and compared with the distribution of alimentary cancer in Ayrshire, where bracken is sparse.
CLUSTERING OF STOMACH CANCER
Previous studies of human cancer in Ayrshire have suggested space/time clustering of alimentary cancer, and this present study has revealed a cluster in space and time of stomach cancer which was most marked in the year of maximum incidence, 1974. This cluster however did not occur in the same Ayrshire, Scotland, between 1958 and 1977 , revealed a 3-fold increase in incidence. This increase, proportionately similar in males and females, is not due to changes in the structure of the population, and an increase of this magnitude has not been reported elsewhere. The cases were classified at the outset of this clinical study by occupational status into "'high" and "'low" risk groups. The high-risk groups consisted of chemical workers, miners, farm and agricultural workers and rubber workers. While there was an increase in incidence in the high-risk group, the most striking increase occurred in the general population group, implying the existence of some as yet unrecognized aetiological factor. The sites within the bladder at which these tumours occurred were similar to published series; however the spectrum of tumour types differed from other British series in having a lower representation of transitional-cell tumours. Whilst these differences may arise from variations in the evaluation of metaplastic change, they may represent a true variation in bladder-cancer histology. (1977, Cancer, 40, 9; Cancer Treat. Rep., 62, 553 In 95 patients with stomach cancer the combination of the levels of the pre-operative levels of serum xi-antichymotrypsin (ACT) and CEA were found to be of use in prognosis. The median survival in weeks according to levels of ACT and CEA (numbers in parentheses) were as follows: ACT <0-8 g/l, CEA normal, 45 weeks (37); ACT >0-8 g/l, CEA normal, 10 weeks (55); ACT >0-8 g/l, CEA raised (>10 ng/ml, Pharmacia assay), 6 weeks (26).
CANCER OF THE LARYNX
This system appears to have potential for predicting the findings at laparotomy, and could help in clinical decision making and the stratification of patients in postoperative trials of chemotherapy. These parameters were also found to be powerful discriminants in the separation of 37 cases of pancreatic cancer from 36 cases of chronic pancreatitis. However, the serum changes in cases of obstructive jaundice due to gall stones were such that the combination of ACT, CEA and routine liver-function tests could not provide a discriminant function to separate these three groups of diseases. Albumin catabolism is reduced in proteincalorie malnutrition but has been reported high in patients with cancer. Albumin metabolism and distribution was studied in a group of cachectic cancer patients with serum albumin concentrations <30 g/l to investigate whether differences in albumin metabolism and the acute-phase response could be detected between patients with anorexia secondary to disseminated malignancy and those with upper gastrointestinal lesions causing reduced dietary intake. Undenatured albumin was specially prepared and labelled with 1311 (McFarlane, 1958, Nature, 182, 53) . Plasma and urinary 1311 was measured to monitor the distribution and rate of excretion of the radioactive catabolic products. Together with the 1311-HSA faecal and urinary losses, the time course of disappearance of 1311-HSA from the plasma was followed until the terminal exponential was established. The fractional catabolic rate (FCR), transcapillary escape rate (TCER) and the distribution of albumin (extravascular to intravascular ratio (E/P) were determined by compartmental analysis (Matthews, 1957, Phys. Med. Biol., 2, 36). Six cachectic cancer patients with > 10% weight loss and no cytotoxic chemotherapy in the preceding month had an elevated FCR, TCER and E/P ratio with an associated acute-phase response. Two patients with reduced food intake for mechanical reasons demonstrated a low FCR consistent with protein-calorie malnutrition, and had only a rnild acute-phase response. In addition, the survival of these two patients was greater than 5 of the patients with high FCR. Adjuvant chemotherapy after mastectomy may prolong disease-free survival, but there is little information on its quality (British Breast Group, 1976, Br. Med. J., ii, 861) . After simple mastectomy, psychiatric morbidity was studied during a trial of adjuvant chemotherapy, patients being randomized to chemotherapy (C), radiotherapy plus chemotherapy (RC) or radiotherapy (R). Morbidity was measured by a self-rating scale, the General Health Questionnaire (GHQ) (Goldberg, 1972; OUP) . Two groups of disease-free survivors were compared: Group I (C and RC) and Group II (R).
Six months after operation, GHQ scores (Table) were similar in both groups. At 12 months, scores had risen in Group I but fallen in Group II, the between-group difference being highly significant. Morbidity remained significantly higher in Group I at both 18 and 24 months after operation. Results indicate that psychiatric illness is commoner in patients completing a one-year course of chemotherapy than in those who had radiotherapy one year before, and that the difference is still evident one year later. In the course of a study on the metabolism and enterohepatic circulation of benzo(a) pyrene (BP), the excretion of radioactivity after i.v. administration (3 ,umol/g) of [14C]_ BP was measured in rabbits and rats. The 0 dose excreted via the bile in 6 h was 350%
(rabbit) and 550 rat). The urine was a relatively minor excretory route in both species. Bile samples (2 h) were incubated with :-glueuronidase, releasing 400o of the 14C into a form extractable with ethyl acetate at pH 7. The extracts were analysed by reversed-phase HPLC. Some 30% of 14C consisted of polar metabolites (possibly polyhydroxylated and/or conjugated). In the rabbit the major aglycone (-350, of extracted 14C) was identified as BP 9,10-diol.
Phenols and quinones accounted for < 15%.
In rat bile extracts, however, only low levels of the 9,10-diol were found (<3%) and the majority of 14C cochromatographed withphenols and quinones (BP 3,6-quinone comprising up to 30%o) and w%ith the 4,5-diol (150°). BBN induces large exophytic lesions in the rat bladder which occur mainly in the dome and median areas and frequently obstruct the lumen. Well-differentiated transitionalcell tumours were observed macroscopically from 12 weeks onwards, with frequent infiltration into the core of the lesion. As time progressed, the mature, flat hexagonal pavement-like superficial cells with angular foldings and ridges of normal luminal membrane were replaced by immature cells of irregular size and shape with a flexible luminal membrane. These cells were often covered by abnormally dense stubby and/or pleomorphic club-ended microvilli. The latter are thought to be indicative of malignant transformation. Capillary endothelial cell processes were frequently seen to breach the basal lamina and approach the urothelium. This may be related to the development of the extensive capillary network in these rapidly growing tumours. There were many abnormalities at the urothelial-mesenchymal junction: microinvasion by epithelial cell processes through the basal lamina; loss, fragmentation and invagination of basal laminae into the epithelium and fusion of the basal laminae of blood capillaries and urothelium. There was frequent invasion of the sub-mucosa by basalcell pseudopodia and multicellular processes attached to the main epithelium by a narrow neck. As the tumours increased in size these lesions were observed more frequently. Their role in carcinogenesis and rapidly growing epithelia was discussed. The effectiveness of antipyrimidine antimetabolites might be enhanced by the concurrent administration of compounds able to modulate selectively the utilization of preformed pyrimidines by tissues; either by prohibiting in tumours, or by enhancing in normal tissues, the "salvage" of preformed pyrimidine. A series of 5-alkyl-substituted deoxyuridines has been studied in relation to the effects of these derivatives on relevant pyrimidine biosynthetic pathways in Ehrlich ascites cells. 5-Ethyl deoxyuridine (EUdR) proved to be the most cytotoxic of the series (ID50 10-5M). It was also the most effective at inhibiting thymidine kinase, for which it is a competitive substrate (Km 70 ,uM). Intracellularly it is further converted to higher phosph-orylated derivatives and is incorporated at low levels into DNA. It appears to have two likely loci of action: inhibition of thymidylate synthetase by its mononucleotide and inhibition of TdR triphosphate incorporation into DNA.
An interesting tissue-specific property of the series proved to be their competitive inhibition of TdR phosphorylase. This enzyme is present in high concentrations in gastrointestinal mucosa and liver (Ki values for EUdR being 0-6M and 5-2mM respectively) but is virtually undetectable in Ehrlichl cells.
When EUdR (400 mg/kg) was administered to tumour-bearing animals it converted slowly to the parent base, accompanied by a 10-fold elevation of TdR in the ascitic fluid. These observations suggest that EUdR or other congeners may be of value in modulating circulating pyrimidine levels, and thus influencing the selective tissue toxicity of antipyrimidines.
RECENT BIOCHEMICAL AND CHEMI-CAL RESULTS WITH 4-(BIS-(2-BRO-MO -PROPYL)AMINO) -2' -CARBOXY -2-METHYLAZOBENZENE Surg., 62, 161) . Recent studies indicate the presence of a factor in the tumour cellfree preparation responsible for raising hepatic citrate content. This factor has been found to be: (i) destroyed by heat-treatment, (ii) non-dialysable, (iii) precipitated by ammonium sulphate fractionation, (iv) present after ultracentrifugation at 240,000 g for 24 h, (v) present in the growth medium of TLX-5 cells grown in vitro, and shown to be virus free.
The effect of this factor on hepatic citrate content is concentration-dependent. From these observations the factor is likely to be a tumour-derived protein and not a viral contaminant. It has been suggested that concentrations of circulating immune complexes (CIC) correlate with tumour response and may form clinically useful tumour markers. This has been tested in gestational trophoblastic neoplasia (GTN) and malignant teratoma (MT) by comparison with the tumour markers already available for these tumours. Concentrations of CIC were measured by quantitating IgG precipitated from serum by 20 polyethylene glycol (Poulton et al., 1978, Lancet, ii, 72) . In GTN, high levels of CIC were found before treatment in 6/23 patients; in 2 of these they fell to normal with a response to chemotherapy, in 1 they remained raised and the tumour failed to respond; in 3 they were persistently raised even thouglh complete response (CR) was achieved. CIC levels became raised during chemotherapy in 7/17 patients in whom they were normal before treatment, although all achieved CR. In MT, levels of CIC were raised before treatment in 5/10 patients. In 4 they became normal with a response to chemotherapy and, in 1 of these, rose again on relapse. In the remaining patient levels remained raised although CR was achieved. In 4/5 patients with normal levels before chemotherapy, CIC rose during treatment, though CR was achieved in 2, and 2 were continuing to respond.
In 
